Skip to main content
Premium Trial:

Request an Annual Quote

Celera Diagnostics, Bristol-Myers Squibb in Major Cardiovascular SNP Study

NEW YORK, Oct. 7-Celera Diagnostics said today that it had struck a deal with Bristol-Myers Squibb to develop drugs and diagnostics for cardiovascular disease and diabetes.


Bristol-Myers will provide more than 3,000 clinical samples from its cholesterol-lowering drug studies to Celera Diagnostics, which will study the prevalence of roughly 1,000 SNPs in this population. By correlating these SNPs with clinical data and drug response, the companies hope to identify therapeutic targets.


The pharmaceutical company will develop and market drugs based on these targets; Celera will retain rights for diagnostic products.


A steering committee will manage the collaboration. Financial terms were not disclosed.

The Scan

Genetic Risk Factors for Hypertension Can Help Identify Those at Risk for Cardiovascular Disease

Genetically predicted high blood pressure risk is also associated with increased cardiovascular disease risk, a new JAMA Cardiology study says.

Circulating Tumor DNA Linked to Post-Treatment Relapse in Breast Cancer

Post-treatment detection of circulating tumor DNA may identify breast cancer patients who are more likely to relapse, a new JCO Precision Oncology study finds.

Genetics Influence Level of Depression Tied to Trauma Exposure, Study Finds

Researchers examine the interplay of trauma, genetics, and major depressive disorder in JAMA Psychiatry.

UCLA Team Reports Cost-Effective Liquid Biopsy Approach for Cancer Detection

The researchers report in Nature Communications that their liquid biopsy approach has high specificity in detecting all- and early-stage cancers.